当前位置: 首页 >> 检索结果
7. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.
作者: Sydel R Parikh.;Nick J Andrews.;Kazim Beebeejaun.;Helen Campbell.;Sonia Ribeiro.;Charlotte Ward.;Joanne M White.;Ray Borrow.;Mary E Ramsay.;Shamez N Ladhani.
来源: Lancet. 2016年388卷10061期2775-2782页
In September, 2015, the UK became the first country to introduce the multicomponent group B meningococcal (MenB) vaccine (4CMenB, Bexsero) into a publicly funded national immunisation programme. A reduced two-dose priming schedule was offered to infants at 2 months and 4 months, alongside an opportunistic catch-up for 3 month and 4 month olds. 4CMenB was predicted to protect against 73-88% of MenB strains. We aimed to assess the effectiveness and impact of 4CMenB in vaccine-eligible infants in England.
9. Caustic ingestion.
作者: Mircea Chirica.;Luigi Bonavina.;Michael D Kelly.;Emile Sarfati.;Pierre Cattan.
来源: Lancet. 2017年389卷10083期2041-2052页
Corrosive ingestion is a rare but potentially devastating event and, despite the availability of effective preventive public health strategies, injuries continue to occur. Most clinicians have limited personal experience and rely on guidelines; however, uncertainty persists about best clinical practice. Ingestions range from mild cases with no injury to severe cases with full thickness necrosis of the oesophagus and stomach. CT scan is superior to traditional endoscopy for stratification of patients to emergency resection or observation. Oesophageal stricture is a common consequence of ingestion and newer stents show some promise; however, the place of endoscopic stenting for corrosive strictures is yet to be defined. We summarise the evidence to provide a plan for managing these potentially life-threatening injuries and discuss the areas where further research is required to improve outcomes.
13. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
作者: Brian G M Durie.;Antje Hoering.;Muneer H Abidi.;S Vincent Rajkumar.;Joshua Epstein.;Stephen P Kahanic.;Mohan Thakuri.;Frederic Reu.;Christopher M Reynolds.;Rachael Sexton.;Robert Z Orlowski.;Bart Barlogie.;Angela Dispenzieri.
来源: Lancet. 2017年389卷10068期519-527页
Lenalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with lenalidomide and dexamethasone has shown significant efficacy in the setting of newly diagnosed myeloma. We aimed to study whether the addition of bortezomib to lenalidomide and dexamethasone would improve progression-free survival and provide better response rates in patients with previously untreated multiple myeloma who were not planned for immediate autologous stem-cell transplant.
16. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).
作者: Ana Maria Henao-Restrepo.;Anton Camacho.;Ira M Longini.;Conall H Watson.;W John Edmunds.;Matthias Egger.;Miles W Carroll.;Natalie E Dean.;Ibrahima Diatta.;Moussa Doumbia.;Bertrand Draguez.;Sophie Duraffour.;Godwin Enwere.;Rebecca Grais.;Stephan Gunther.;Pierre-Stéphane Gsell.;Stefanie Hossmann.;Sara Viksmoen Watle.;Mandy Kader Kondé.;Sakoba Kéïta.;Souleymane Kone.;Eewa Kuisma.;Myron M Levine.;Sema Mandal.;Thomas Mauget.;Gunnstein Norheim.;Ximena Riveros.;Aboubacar Soumah.;Sven Trelle.;Andrea S Vicari.;John-Arne Røttingen.;Marie-Paule Kieny.
来源: Lancet. 2017年389卷10068期505-518页
rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa.
20. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
作者: Feng-Cai Zhu.;Alie H Wurie.;Li-Hua Hou.;Qi Liang.;Yu-Hua Li.;James B W Russell.;Shi-Po Wu.;Jing-Xin Li.;Yue-Mei Hu.;Qiang Guo.;Wen-Bo Xu.;Abdul R Wurie.;Wen-Juan Wang.;Zhe Zhang.;Wen-Jiao Yin.;Manal Ghazzawi.;Xu Zhang.;Lei Duan.;Jun-Zhi Wang.;Wei Chen.
来源: Lancet. 2017年389卷10069期621-628页
A recombinant adenovirus type-5 vector-based vaccine expressing the glycoprotein of Ebola Zaire Makona variant showed good safety and immunogenicity in a phase 1 trial of healthy Chinese adults. We aimed to assess the safety and immunogenicity of this vaccine in healthy adults in Sierra Leone and to determine the optimal dose.
|